(Telestock) – Pfizeran American pharmaceutical giant, and BioNTecha German biotechnology and biopharmaceutical company, announced that, in a Phase 3 study, the combined influenza and COVID-19 vaccine candidate has achieved one of its two primary objectives of immunogenicity.
The combination candidate consists of Pfizer’s mRNA influenza vaccine candidate with the companies’ licensed COVID-19 vaccine. The Phase 3 study measured two primary immunogenicity endpoints (immunogenicity against SARS-CoV-2 and immunogenicity against influenza A and B), of which one was met.
“The study did not meet one of its primary immunogenicity endpoints of non-inferiority against Influenza B strain despite achieving higher influenza A responses and comparable COVID-19 responses compared to comparator vaccines,” it said in a statement.
In a separate Phase 2 study, Pfizer evaluated standalone mRNA influenza vaccine candidates trivalent (tIRV) that have demonstrated “robust immunogenicity”.
The companies “are evaluating modifications to the combined vaccine candidate aimed at improving immune responses against influenza B and will discuss next steps with health authorities.”